Coeptis Therapeutics Raises $1.5M Via Convertible Notes
Ticker: COEPW · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1759186
Sentiment: neutral
Topics: financing, debt-offering, convertible-notes
TL;DR
Coeptis just raised $1.5M in debt, maturing next year, to fund operations.
AI Summary
On December 12, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing the closing of a private placement of convertible promissory notes. The company raised approximately $1.5 million in gross proceeds from the sale of these notes, which mature on December 12, 2025, and bear interest at 8% per annum. The funds are intended for general corporate purposes.
Why It Matters
This capital raise provides Coeptis Therapeutics with additional funding for its operations, potentially supporting its drug development pipeline and strategic initiatives.
Risk Assessment
Risk Level: medium — The company raised funds through debt, which adds financial obligations and interest payments, and the use of convertible notes can lead to dilution for existing shareholders.
Key Numbers
- $1.5M — Gross Proceeds (Raised from private placement of convertible promissory notes.)
- 8% — Interest Rate (Annual interest rate on the convertible promissory notes.)
- 1 year — Maturity (The convertible promissory notes mature on December 12, 2025.)
Key Players & Entities
- Coeptis Therapeutics Holdings, Inc. (company) — Registrant
- December 12, 2024 (date) — Date of Report
- $1.5 million (dollar_amount) — Gross proceeds from private placement
- December 12, 2025 (date) — Maturity date of convertible promissory notes
- 8% (percentage) — Annual interest rate on notes
FAQ
What was the total amount of gross proceeds raised by Coeptis Therapeutics in the private placement?
Coeptis Therapeutics raised approximately $1.5 million in gross proceeds from the sale of convertible promissory notes.
When do the convertible promissory notes issued by Coeptis Therapeutics mature?
The convertible promissory notes mature on December 12, 2025.
What is the annual interest rate on the convertible promissory notes?
The convertible promissory notes bear interest at a rate of 8% per annum.
What is the intended use of the funds raised by Coeptis Therapeutics?
The funds raised are intended for general corporate purposes.
What was the former name of Coeptis Therapeutics Holdings, Inc.?
The former name of Coeptis Therapeutics Holdings, Inc. was Bull Horn Holdings Corp., with a date of name change on November 15, 2018.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-12-16 19:00:07
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COEP Nasdaq Capital Mark
- $11.50 — e-half of one share of Common Stock for $11.50 per whole share COEPW Nasdaq Capita
Filing Documents
- coeptis_8k.htm (8-K) — 31KB
- coeptis_ex9901.htm (EX-99.1) — 16KB
- 0001683168-24-008765.txt ( ) — 266KB
- coep-20241212.xsd (EX-101.SCH) — 3KB
- coep-20241212_def.xml (EX-101.DEF) — 26KB
- coep-20241212_lab.xml (EX-101.LAB) — 36KB
- coep-20241212_pre.xml (EX-101.PRE) — 25KB
- coeptis_8k_htm.xml (XML) — 5KB
01
Item 8.01 Other Events On December 12, 2024, Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis") issued a press release announcing the entering into of a letter of intent with a risk mitigation software company for the acquisition by Coeptis of certain assets from such company in support of Coeptis' planned expansion into the technology space. The closing of this transaction is subject to preparation and execution of definitive documents . A copy of the press release is included with the Current Report on Form 8-K .
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No . Description 99.1 Press Release, dated December 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Coeptis Therapeutics Holdings, Inc. Date: December 16, 2024 By: /s/ David Mehalick David Mehalick Chief Executive Officer 3